APA (7th ed.) Citation

T, W., P, L., L, X., L, G., X, N., G, T., . . . J, Y. (2024). CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: A post-hoc, propensity score-matched, cohort study in Chinese patients. Annals of hematology, 103(2), 575. https://doi.org/10.1007/s00277-023-05513-x

Chicago Style (17th ed.) Citation

T, Wang, et al. "CEAC (oral Semustine, Etoposide, Cytarabine and Cyclophosphamide) Vs BEAM (carmustine, Etoposide, Cytarabine, and Melphalan) Conditioning Regimen of Autologous Stem Cell Transplantation for Diffuse Large B-cell Lymphoma: A Post-hoc, Propensity Score-matched, Cohort Study in Chinese Patients." Annals of Hematology 103, no. 2 (2024): 575. https://doi.org/10.1007/s00277-023-05513-x.

MLA (9th ed.) Citation

T, Wang, et al. "CEAC (oral Semustine, Etoposide, Cytarabine and Cyclophosphamide) Vs BEAM (carmustine, Etoposide, Cytarabine, and Melphalan) Conditioning Regimen of Autologous Stem Cell Transplantation for Diffuse Large B-cell Lymphoma: A Post-hoc, Propensity Score-matched, Cohort Study in Chinese Patients." Annals of Hematology, vol. 103, no. 2, 2024, p. 575, https://doi.org/10.1007/s00277-023-05513-x.